Cargando…

Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland

Background: Enhanced vaccines (e.g., containing adjuvants) have shown increased immunogenicity and effectiveness in older adults, who often respond sub-optimally to conventional influenza vaccines. In this study, we evaluated the cost-effectiveness of an inactivated, seasonal, MF59-adjuvanted quadri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Van Hung, Ashraf, Mansoor, Mould-Quevedo, Joaquin F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10221880/ https://www.ncbi.nlm.nih.gov/pubmed/37243037 http://dx.doi.org/10.3390/vaccines11050933

Ejemplares similares

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
por: Urueña, Analia, et al.
Publicado: (2021)

Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Children: A Narrative Review
por: Mould-Quevedo, Joaquin F., et al.
Publicado: (2023)

The Epidemiological and Economic Impact of a Cell-Based Quadrivalent Influenza Vaccine in Adults in the US: A Dynamic Modeling Approach
por: Nguyen, Van Hung, et al.
Publicado: (2021)

Cost-Effectiveness of Vaccination of Older Adults with an MF59(®)-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden
por: Jacob, Jorge, et al.
Publicado: (2023)

Estimating the impact of influenza vaccination of low-risk 50–64-year-olds on acute and ICU hospital bed usage in an influenza season under endemic COVID-19 in the UK
por: Nguyen, Van Hung, et al.
Publicado: (2023)

Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
por: Krishnarajah, Girishanthy, et al.
Publicado: (2021)

Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population
por: Rumi, Filippo, et al.
Publicado: (2023)

A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019–2020 Influenza Season in the United States
por: Divino, Victoria, et al.
Publicado: (2021)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

Estimating the Impact of Influenza Vaccination on Acute and ICU Hospital Bed Usage in an Influenza Season under Endemic COVID-19 in the US
por: Nguyen, Van Hung, et al.
Publicado: (2022)

The Impact of Adjuvanted Influenza Vaccine on Disease Severity in the US: A Stochastic Model
por: Pelton, Stephen I., et al.
Publicado: (2023)

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
por: Thorrington, Dominic, et al.
Publicado: (2017)

Evaluating the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to High-Dose Trivalent and Other Egg-Based Influenza Vaccines among Older Adults in the US during the 2017–2018 Influenza Season
por: Pelton, Stephen I., et al.
Publicado: (2020)

25. Relative Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-Based Trivalent High-Dose Influenza Vaccine among U.S. Older Adults during 2019-20 Influenza Season
por: levin, myron J, et al.
Publicado: (2021)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

29. Impact of Enhanced Influenza Vaccines on Direct Healthcare Costs for the U.S. Elderly: A Comprehensive Real-World Evaluation of Adjuvanted Trivalent Influenza Vaccine Compared to Trivalent High-Dose Influenza Vaccine for the 2018–19 Influenza Season
por: Postma, Maarten, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Cell Versus Egg-Based Seasonal Influenza Vaccination in Children and Adults in Argentina
por: Urueña, Analía, et al.
Publicado: (2022)

Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines
por: Thommes, Edward W., et al.
Publicado: (2016)

1167. The Value of Influenza Vaccination in the Older Adult Population. A Stochastic Model Estimation of the benefit of vaccination to prevent the Severe Outcomes in the U.S.
por: Pelton, Stephen I, et al.
Publicado: (2023)

Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada
por: Nguyen, Van Hung, et al.
Publicado: (2022)

Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
por: Kim, Yun-Kyung, et al.
Publicado: (2018)

Impact of General Practitioner Education on Acceptance of an Adjuvanted Seasonal Influenza Vaccine among Older Adults in England
por: de Lusignan, Simon, et al.
Publicado: (2023)

6. MF59 ASSURANCE 2: A Real-world Study to Estimate the Relative Vaccine Effectiveness of Adjuvanted Trivalent Influenza Vaccine Compared to Egg-based Trivalent High-dose Among U.S. Older Adults During 2018–19 Influenza Season
por: Pelton, Stephen I, et al.
Publicado: (2020)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

14. A Comprehensive Real-World Analysis to Compare Adjuvanted Trivalent Influenza Vaccine and Trivalent High Dose Influenza Vaccine by Age and Period of High Influenza Activity for the 2018–19 Season among U.S. Elderly
por: Postma, Maarten, et al.
Publicado: (2020)

1168. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom
por: Maschio, Michael, et al.
Publicado: (2022)

Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis
por: Coleman, Brenda L., et al.
Publicado: (2021)

Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
por: Amicizia, Daniela, et al.
Publicado: (2023)

Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain
por: García, Amos, et al.
Publicado: (2016)

Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season
por: Jagielska, Anna M., et al.
Publicado: (2021)

Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection
por: Kackos, Christina M., et al.
Publicado: (2023)

Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany
por: Molnar, Daniel, et al.
Publicado: (2022)

Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis
por: Levin, Myron J., et al.
Publicado: (2021)

Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia
por: Aljunid, Syed Mohamed, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a5e4jht03euhv42t3ln27pudu2